Fouad Namouni, MD
The European Commission has approved dasatinib (Sprycel) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to Bristol-Myers Squibb, the manufacturer of the TKI.
In November 2017, the FDA expanded the approval of dasatinib to include pediatric patients with Ph-positive CML-CP; the European Commission granted the same indication in July 2018.
Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Posted December 9, 2017. Accessed February 11, 2019. https://bit.ly/2MEcNta?rel=0.
... to read the full story